[4]
Hsiao, Y.H.; Chou, M.C.; Flower, C.; Mason, J.T.; Man, Y.G. Breast cancer heterogeneity: Mechanisms, proofs and implications. J. Cancer, 2010, 1, 6-13.
[5]
Becker, S. A historic and scientific review of breast cancer: The next global health care challenge. Intl. J. Gyne. Obste., 2015, 131, S36-S39.
[7]
Clezardin, P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res., 2011, 13, 207-215.
[8]
Ravnan, M.C.; Ravnan, S.L.; Walberg, M.P. Metastatic breast cancer: A review of current and novel pharmacotherapy. Formulary, 2011, 46, 130-146.
[9]
Cardoso, F.; Senkus-Kone, E.; Fallowfield, L.; Costa, A.; Castigilone, M. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann. Oncol., 2010, 21, 15-19.
[10]
Pagani, O.; Senkus, E.; Wood, W.; Colleoni, M.; Cufer, T.; Kyriakides, S.; Costa, A.; Winer, E.P.; Cardoso, F. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? J. Natl. Cancer Inst., 2010, 102, 456-463.
[11]
Sashidhara, K.V.; Kumar, M.; Sonkar, R.; Singh, B.S.; Khanna, A.K.; Bhatia, G. Indole based fibrates as potential hypolipidemic and anti-obesity agents. J. Med. Chem., 2012, 55, 2769-2779.
[12]
Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.Y.; Yuan, C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J. Biol. Chem., 2004, 279, 48071-48078.
[13]
Musa, A.M.; Cooperwood, J.S.; Khan, M.O.F. A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer. Curr. Med. Chem., 2008, 15(26), 2664-2679.
[14]
Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A. DiOrio. C.; Doty, J.; Morin, M.J.; Moyer, M.P.I nduction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 1997, 57, 4838-4848.
[15]
Lewis, J.S.; Jordan, V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anti-carcinogenesis and drug resistance. Mutat. Res. Fundam. Mol. Mech. Mutagen., 2005, 591, 247-263.
[16]
Harada, K.; Kubo, H.; Tomigahara, K.; Nishioka, K.; Takahashi, J.; Momose, M.; Inoue, S.; Kojima, A. Coumarins as novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. Bioorg. Med. Chem. Lett., 2010, 20, 272-275.
[17]
Sashidhara, K.V.; Kumar, A.; Kumar, M.; Sarkar, J.; Sinha, S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Lett., 2010, 20, 7205-7211.
[19]
Adriano, D.A.; Lívia, B.S.; Donald, J.A. Structure-Based Drug Design Strategies in Medicinal Chemistry. Curr. Top. Med. Chem., 2009, 9(9), 771-790.
[20]
Shaveta, Mishra S.; Singh, P. Hybrid molecules: The privileged scaffolds for various pharmaceuticals. Eur. J. Med. Chem., 2016, 124, 500-536.
[21]
Ballazhi, L.; Popovski, E.; Jashari, A.; Imeri, F.; Ibrahimi, I.; Mikhova, B.; Mladenovska, K. Potential anti-proliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediatedbone and lung metastases. Acta Pharm., 2015, 65, 53-63.
[22]
Sashidhara, K.V.; Avula, S.R.; Sharma, K.; Palnati, K.; Bathula, S.R. Discovery of coumarin-monastrol hybrid as potential anti-breast tumor-specific agent. Eur. J. Med. Chem., 2013, 60, 120-127.
[23]
You, L.; An, R.; Wang, X.; Li, M. Discovery of novel osthole derivatives as potential anti-breast cancer treatment. Bioorg. Med. Chem. Lett., 2010, 20, 7426-7428.
[24]
Patel, K.; Karthikeyan, C.; Solomon, V.R.; Moorthy, H.R.; Lee, H.; Sahu, K.; Deora, G.S.; Trivedi, P. Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines. Lett. Drug Des. Discov., 2011, 8(4), 308-311.
[25]
Kahveci, B.; Yilmaz, F.; Mentese, E.; Ulker, S. Design, synthesis and biological evaluation of coumarin-triazole hybrid molecules as potential antitumor and Pancreatic lipase agents. Arch. Pharm. Chem. Life Sci., 2017, 350 e1600369
[26]
Reddy, N.S.; Mallireddigari, M.R.; Cosenza, S.; Gumireddy, K.; Bell, S.C.; Reddy, P.K.; Reddy, M.V. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg. Med. Chem. Lett., 2004, 14, 4093-4097.
[27]
Chen, H.; Li, S.; Yao, Y.; Zhou, L.; Zhao, J.; Gu, Y.; Wang, K.; Li, X. Design, synthesis and anti-tumor activities of novel triphenylethylene-coumarin hybrids, and their interactions with Ct-DNA. Bioorg. Med. Chem. Lett., 2013, 23(17), 4785-4789.
[28]
Paul, K.; Bindal, S.; Luxmi, V. Synthesis of new conjugated coumarin–benzimidazole hybrids and their anticancer activity. Bioorg. Med. Chem. Lett., 2013, 23(12), 3667-3672.
[29]
Chand, K.; Shirazi, A.N.; Yadav, P.; Tiwari, R.K.; Kumari, M.; Parang, K.; Sharma, S.K. Synthesis, anti-proliferative and c-Src kinase inhibitory activities of cinnamoyl- and pyranochromen-2-one derivatives. Can. J. Chem., 2013, 91(8), 741-754.
[30]
Amir, E.; Freedman, O.C.; Seruga, B.; Evans, D.G. Assessing women at high risk of breast cancer: A review of risk assessment models. J. Natl. Cancer Inst., 2010, 102, 680-691.
[31]
Banting, L.; Nicholls, P.J.; Shaw, M.A.; Smith, H.J. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer. Prog. Med. Chem., 1989, 26, 253-298.
[32]
Stefenachi, A.; Favia, A.D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; Hartmann, R.W.; Carotti, A. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/c17-20 lyase. J. Med. Chem., 2011, 54, 1613-1625.
[33]
Xiao, C.F. Tao, Li Y.; Sun, H.Y.; Wei, W.; Chen, Y.; Fu Li, W.; Zou, Y. Design, synthesis and antitumor activity of a series of novel coumarin-stilbenes hybrids, the 3-aryl coumarins. Chin. Chem. Lett., 2010, 21, 1295-1298.
[34]
Hussain, M.K.; Sigh, D.K.; Singh, A.; Asad, M.; Ansari, I.; Shameem, M.; Krishna, S.; Valicherla, G.R.; Makadia, V.; Meena, S.; Deshmukh, A.L.; Gayen, J.R.; Siddiqui, M.I.; Datta, D.; Hajela, K.; Banerjee, D.A. Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitorwith in vitro and in vivo anti-tumor activity in breast cancer models. Sci. Rep., 2017, 7, 10715.
[35]
Devraj, R.; Barrett, J.F.; Fernandez, J.A.; Katzenellenbogen, J.A.; Cushman, M. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. J. Med. Chem., 1996, 39, 3367-3374.
[36]
Krohn, K.; Kulikowski, K.; Leclercq, G. Diethylstilbestrol-linked cytotoxic agents: synthesis and binding affinity for estrogen receptors. J. Med. Chem., 1989, 32, 1532-1538.
[37]
Musa, M.A.; Khan, M.O.; Cooperwood, J.S. Synthesis and antiproliferative activity of coumarin-estrogenconjugates against breast cancer cell lines. Lett. Drug Des. Discov., 2009, 6(2), 133-138.
[38]
Kamath, P.R.; Sunil, D.; Joseph, M.M.; Salam, A.; Sreelekha, T. Indole-coumarin-thiadiazole hybrids: An appraisal of their MCF-7 cell growth inhibition, apoptotic, antimetastatic and computational Bcl-2 binding potential. Eur. J. Med. Chem., 2017, 136, 442-451.
[39]
Liu, M.M.; Chen, X.Y.; Huang, Y.Q.; Feng, P. Guon, Ya-Lan.; Yang, G.; Chen, Y. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents. J. Med. Chem., 2014, 57(22), 9343-9356.
[40]
Kamath, P.R.; Sunil, D.; Ajees, A.; Pai, K.S.R.; Das, S. Some new coumarin-indole hybrids: Synthesis, anti-cancer and Bcl-2 docking studies. Bioorg. Chem., 2015, 63, 101-109.
[42]
Morsy, S.A.; Farahat, A.A.; Nasr, M.N.A.; Tanatawy, A.S. Synthesis, molecular modelling and anti-cancer activity of new coumarin containing compounds. Saudi Pharm. J., 2017, 25, 873-883.
[44]
Kini, S.G.; Choudhary, S.; Mubeen, M. Synthesis, docking and anti-cancer activity of coumarin substituted derivatives of benzothiazole. J. Comput. Methods Mol. Des, 2012, 2, 51-60.
[45]
Goel, R.; Luxami, V.; Paul, K. Synthesis, in vitro anticancer activity and SAR studies of arylated imidazo[1,2-a] pyrazine-coumarin hybrids. RSC Advances, 2015, 5, 37887-37895.